Hepatitis%20a%20-and-%20e Treatment

Treatment

General Care

Supportive Care

Consider hospitalization if there is vomiting, dehydration, signs of hepatic decompensation
Screen for other sexually-transmitted diseases (STDs) in cases of sexually-acquired hepatitis or if otherwise appropriate

Hepatitis A

Supportive therapy is recommended; treatment for nausea and diarrhea should be given

Hepatitis E

Hepatitis E is a self-limiting disease and supportive therapy may be offered
Patients with severe acute hepatitis E or HEV-associated liver failure, or immunocompromised patients with chronic HEV may benefit from antiviral drugs (eg Ribavirin)

For immunocompromised patients with chronic HEV with persistent HEV detected by HEV RNA serum/stool testing after 12 weeks of Ribavirin treatment, additional 3 months monotherapy with Ribavirin may be considered
Pegylated interferon-α is a treatment option for liver transplant patients unresponsive to Ribavirin monotherapy

Product Highlight - Salofalk

12 Mar 2021

SALOFALK – Mesalazine 1.5 g PR granules

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.

Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma

Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).